244 related articles for article (PubMed ID: 32251844)
1. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A; Lellouche J; Temkin E; Daikos G; Skiada A; Durante-Mangoni E; Dishon-Benattar Y; Bitterman R; Yahav D; Daitch V; Bernardo M; Iossa D; Zusman O; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L; Paul M; Carmeli Y;
Clin Microbiol Infect; 2020 Sep; 26(9):1185-1191. PubMed ID: 32251844
[TBL] [Abstract][Full Text] [Related]
2. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
3.
Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
[TBL] [Abstract][Full Text] [Related]
4. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
7. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
[TBL] [Abstract][Full Text] [Related]
8. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
[TBL] [Abstract][Full Text] [Related]
9. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E.coli and Klebsiella pneumoniae by checkerboard method.
Dhandapani S; Sistla S; Gunalan A; Manoharan M; Sugumar M; Sastry AS
Indian J Med Microbiol; 2021 Jan; 39(1):6-10. PubMed ID: 33516606
[TBL] [Abstract][Full Text] [Related]
10. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
Ni W; Wang Y; Ma X; He Y; Zhao J; Guan J; Li Y; Gao Z
Eur J Clin Microbiol Infect Dis; 2022 Dec; 41(12):1451-1457. PubMed ID: 36201141
[TBL] [Abstract][Full Text] [Related]
12. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
Marie MA; Krishnappa LG; Alzahrani AJ; Mubaraki MA; Alyousef AA
Bosn J Basic Med Sci; 2015 Oct; 15(4):24-9. PubMed ID: 26614848
[TBL] [Abstract][Full Text] [Related]
15. The distribution of carbapenem- and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India.
Manohar P; Shanthini T; Ayyanar R; Bozdogan B; Wilson A; Tamhankar AJ; Nachimuthu R; Lopes BS
J Med Microbiol; 2017 Jul; 66(7):874-883. PubMed ID: 28671537
[TBL] [Abstract][Full Text] [Related]
16. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia.
Khalili H; Shojaei L; Mohammadi M; Beigmohammadi MT; Abdollahi A; Doomanlou M
J Comp Eff Res; 2018 Sep; 7(9):901-911. PubMed ID: 30192166
[TBL] [Abstract][Full Text] [Related]
17. Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
Dickstein Y; Lellouche J; Schwartz D; Nutman A; Rakovitsky N; Dishon Benattar Y; Altunin S; Bernardo M; Iossa D; Durante-Mangoni E; Antoniadou A; Skiada A; Deliolanis I; Daikos GL; Daitch V; Yahav D; Leibovici L; Rognås V; Friberg LE; Mouton JW; Paul M; Carmeli Y;
Clin Infect Dis; 2020 Dec; 71(10):2599-2607. PubMed ID: 31758195
[TBL] [Abstract][Full Text] [Related]
18. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
20. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
Shah PG; Shah SR
J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
